Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.

Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE Jr, Bailey JR.

J Clin Invest. 2019 Aug 13;130. pii: 130720. doi: 10.1172/JCI130720.

2.

Outflanking immunodominance to target subdominant broadly neutralizing epitopes.

Angeletti D, Kosik I, Santos JJS, Yewdell WT, Boudreau CM, Mallajosyula VVA, Mankowski MC, Chambers M, Prabhakaran M, Hickman HD, McDermott AB, Alter G, Chaudhuri J, Yewdell JW.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13474-13479. doi: 10.1073/pnas.1816300116. Epub 2019 Jun 18.

PMID:
31213541
3.

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91. doi: 10.1073/pnas.1718441115. Epub 2017 Dec 18.

4.

Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.

El-Diwany R, Cohen VJ, Mankowski MC, Wasilewski LN, Brady JK, Snider AE, Osburn WO, Murrell B, Ray SC, Bailey JR.

PLoS Pathog. 2017 Feb 24;13(2):e1006235. doi: 10.1371/journal.ppat.1006235. eCollection 2017 Feb.

Supplemental Content

Loading ...
Support Center